Curatis Holding AG is a Swiss-based specialty pharmaceutical company dedicated to the acquisition, development, and commercialization of innovative medicines for rare and specialty care diseases. Operating primarily in two business areas, it holds exclusive distribution rights for over 40 products in Switzerland, targeting orphan conditions such as Chorea Huntington, Wilson’s Disease, CMV retinitis, epilepsy, and bladder cancer, with ambitions to expand into key European markets including Germany, France, the UK, and Italy. In its development pipeline, Curatis advances promising candidates like C-PTBE-01 for peritumoral brain edema in pediatric patients, C-AM-01 for severe migraine with aura, C-MOH-01 for medication overuse headache, and KIN001 for rare inflammatory and fibrotic diseases such as Idiopathic Pulmonary Fibrosis, leveraging existing safety data for accelerated progress. Founded by industry veterans and led by an experienced executive team including CEO Dr. Roland Rutschmann and Chief Corporate Development Officer Günter Graubach, alongside a distinguished advisory board of oncology, neurology, and drug development experts, Curatis Holding AG addresses critical unmet needs in the European biotech sector focused on orphan and specialty therapeutics.